Purchase Short-Term Access

Adverse Events with 4 Months of Rifampin Therapy or 9 Months of Isoniazid Therapy for Latent Tuberculosis Infection: A Randomized Trial
Dick Menzies, MD, MSc; Richard Long, MD; Anete Trajman, MD, PhD; Marie-JoseĢe Dion, MSc; Jae Yang, MD; Hamdan Al Jahdali, MD; Ziad Memish, MD; Kamran Khan, MD, MPH; Michael Gardam, MD; Vernon Hoeppner, MD; Andrea Benedetti, PhD; Kevin Schwartzman, MD, MPH
Annals of Internal Medicine 2008;149:689-697. doi:10.7326/0003-4819-149-10-200811180-00003

Purchase Online access to this article for 24 hours
Buy Now

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.